ABSI

AbsciD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

25%

Probability

Target price

$4.21

-33.7% vs current

Most likely

Base case

50%

Probability

Target price

$2.34

-63.1% vs current

B-

Bear case

25%

Probability

Target price

$1.17

-81.6% vs current

AI sentiment snapshot

Latest data as of 2025-11-17

AI commentary

Market sentiment is cautious-to-mixed: investors price in high binary risk from platform milestones and financing needs while some buyers speculate on licensing upside [#PR-2025-07-20], [#10-Q-2025-Q2p12]. Short-term volume spikes follow news releases, indicating event-driven trading rather than steady accumulation [#Market-2025-11].

RankAlpha Sentiment AI - 2025-11-17

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-03-31eventUpcoming clinical or partnership updates for protein-engineering platformHigh impact

Absci's platform and collaborations can produce binary updates (trial milestones, partner licensing deals) that materially move valuation; prior PRs and collaborator announcements were drivers of volatility [#PR-2025-04-15], [#10-Q-2025-Q2p3].

2026-06-30catalystCash runway / financing needHigh impact

Small-cap biotech with ongoing R&D spend faces dilution risk if cash runway shortens; a financing announcement or unexpected cash burn increase could depress share price [#10-Q-2025-Q2p12].

2026-12-31catalystCommercialization / licensing winHigh impact

A favorable licensing deal or initial commercialization of a discovery from Absci's platform could re-rate shares higher given limited current revenue [#PR-2025-07-20].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2025-11-17 • Updated nightlySource: Internal modelMethodology